Neonatal hyperglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:55:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neonatal hyperglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Oral Glibenclamide for Managing High Blood Sugar in Premature Infants Weighing Less Than 1500g https://clinicaltrials.eu/trial/study-on-oral-glibenclamide-for-managing-high-blood-sugar-in-premature-infants-weighing-less-than-1500g/ Wed, 29 Apr 2026 14:28:03 +0000 https://clinicaltrials.eu/trial/study-on-oral-glibenclamide-for-managing-high-blood-sugar-in-premature-infants-weighing-less-than-1500g/ This clinical trial is focused on studying a condition known as transient hyperglycemia in premature infants. Transient hyperglycemia is a temporary increase in blood sugar levels that can occur in babies born before their due date. The study will use a treatment called glibenclamide, which is given as an oral suspension. This means the medicine is in liquid form and can be taken by mouth or through a feeding tube.

The purpose of the study is to see how well glibenclamide works in controlling high blood sugar levels in premature infants who weigh less than 1500 grams. The study will last for a short period, specifically looking at the effects over 72 hours. During this time, researchers will monitor the infants to see if the treatment helps manage their blood sugar without needing additional treatments like insulin. The study will also check for any side effects and how the infants grow and develop while on the treatment.

Throughout the study, the infants will be closely observed to ensure their safety and well-being. The researchers will look at various factors, such as how the infants’ blood sugar levels change, any reactions to the medication, and overall health outcomes. The goal is to gather information that could help improve the care and treatment of premature infants with high blood sugar levels in the future.

]]>